DIMA Biotechnology LTD is a biotechnology company specializing in membrane protein production and monoclonal antibody development. All our products are developed using our own proprietary platforms with a focus on druggable targets.

We offer several solutions for full-length multipass transmembrane proteins including VLP, MNP, Synthetic Nanodisc, Exosome and Detergent extraction. Most of our proteins are validated by functional assays and SDS-PAGE.

We also have a proprietary single B cell cloning platform,DimAb® single B cloning platform, for recombinant monoclonal antibody (mAb) development which can efficiently generate many diversified mAbs and acquire the antibody sequences in a high-throughput way. Combined with our antibody engineering and functional assay evaluation services, we can provide integrated solutions for scientific research, clinical diagnosis, and therapeutic R&D.